Determination of clinical and luteolytic effectiveness of a prostaglandin analog in mares by a dose response study.

Article Details

Citation
Copy to clipboard

Hamm D, Witherspoon DM, Buell JR, Chen CL, Jochle W

Determination of clinical and luteolytic effectiveness of a prostaglandin analog in mares by a dose response study.

Theriogenology. 1981 Oct;16(4):447-57.

PubMed ID
16725656 [ View in PubMed
]
Abstract

In trials covering two seasons, 124 thoroughbred and 40 quarterhorse mares with either normal cycles (55 diestrous mares, 33 postpartum mares after foal heat) or in anestrus during the breeding season (76) were treated with either a novel PGF analog K 11941 or with the PGF analog prostalene (Synchrocept(trade mark)). K 11941 was used over a range of doses from 0.5 to 4.5 mg, while prostalene was applied at the recommended dose level of 2 mg. Blood progesterone determinations, clinical observations and the results of breeding confirmed that K 11941, at doses of 2 mg or larger, and prostalene, were effective and safe luteolysins; heat and ovulations occurred within the expected time intervals and fertility was satisfactory. Clinical data were converted into a response score (CRS) and an added fertility score (CRSF) for statistical evaluation and the establishment of a dose response curve. In both scores, 0.5 to 1.5 mg were significantly less effective than the higher dose levels (p<.0001). No significant differences were found for the 2 and 3 mg dose of K 11941 in diestrous and anestrous mares. In both indications, prostalene scored less (p<.05). Data analysis and establishment of a dose response curve point to 3 mg of K 11941 as the optimal dose.

DrugBank Data that Cites this Article

Drugs